Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cost-effectiveness
100%
Clinical Efficacy
100%
Economic Evaluation
100%
Pegvisomant
100%
Clinical Costs
100%
Review Evaluation
100%
Growth Factors
44%
Insulin-like
44%
Growth Hormone
33%
Disease Symptoms
22%
Synthesis of Evidence
11%
Cardiovascular Disease
11%
Quality of Life
11%
Lower Limit
11%
Highly Effective
11%
Radiotherapy
11%
Tumor Size
11%
Pituitary Tumor
11%
Nonrandomized Studies
11%
Metabolic
11%
Liver Enzymes
11%
Hormone Levels
11%
Pharmacotherapy
11%
Incremental Cost-effectiveness Ratio
11%
Patient Compliance
11%
Genetic Engineering
11%
Economic Model
11%
Life Expectancy
11%
Drug Costs
11%
Patient Safety
11%
Hypersecretion
11%
Hormone Analogs
11%
Orphan Disease
11%
Narrative Synthesis
11%
Therapy Efficacy
11%
Adverse Events Profile
11%
Fourth Line
11%
Analytical Economic Model
11%
If Current
11%
Nursing and Health Professions
Systematic Review
100%
Clinical Effectiveness
100%
Cost Effectiveness Analysis
100%
Economic Evaluation
100%
Acromegaly
100%
Pegvisomant
100%
Somatomedin C
44%
Diseases
44%
Physical Disease by Body Function
33%
Quality Adjusted Life Year
22%
Growth Hormone
22%
Drug Therapy
11%
Patient Compliance
11%
Quality of Life
11%
Adverse Event
11%
Hypophysis Tumor
11%
Incremental Cost-Effectiveness Ratio
11%
Drug Cost
11%
Life Expectancy
11%
Tumor Volume
11%
Orphan
11%
Liver Enzyme
11%
Growth Hormone Derivative
11%
Radiotherapy
11%
Pharmacology, Toxicology and Pharmaceutical Science
Acromegaly
100%
Pegvisomant
100%
Somatomedin C
44%
Diseases
44%
Physical Disease by Body Function
33%
Growth Hormone
22%
Neoplasm
11%
Randomized Controlled Trial
11%
Adverse Event
11%
Pharmacotherapy
11%
Life Expectancy
11%
Hypophysis Tumor
11%
Growth Hormone Derivative
11%
Liver Enzyme
11%